Amarin Corp Plc (AMRN)

[jessellivermore]

Vascepa as an adjuvant treating highly lethal breast cancer....

Thanx raf for bringing this to my attention...N.B. this has been peer reviewed


http://europepmc.org/articles/PMC6430703

File under huge deal...

Its called "triple negative breast cancer "TNBC"...because these cancer do not respond to estrogens, progesterone or HER...TNBC comprises 10-20 of all breast cancers and is the the most lethal variety metastasizing early and is almost universally fatal..

TNBC cells are characterised by cell membrane receptors called EPHA2 that are capable of producing some highly inflammatory eicosanoids which can support growth of the malignancy and fend off attacks by the bodies defense systems...Previous studies using omega-3s like Lovaza show omega 3s can have a temporary effect on cancer cells..But are ineffective in treating solid tumors...

The authors here through extensive scientific investigation which includes graphing TNBC tumors to mice have shown a combination that uses either genetic segments to prevent the function of the tumor's EPHA2 receptors or agents which destroy the receptors...Will render the cancer cell vulnerable to EPA (Vascepa in calculated therapeutic does was used),

Addition of EPA (Vascepa) in tumor cells with reduced EPHA2 membrane receptors was highly effective in killing these cancer cells. EPA caused changes in cholesterol activity which led to changes in cellular membranes which triggered apoptosis...

Interestingly EPHA2 receptors are found on other very aggressive cancers in organs other than the breasts which are highly lethal...

This is something Amarin needs to look into...

":>) JL